Revolution Medicines agrees to buy US drugmaker EQRx
The transaction is intended to add more than $1bn in net cash to Revolution Medicines’ balance sheet and…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
02 Aug 23
The transaction is intended to add more than $1bn in net cash to Revolution Medicines’ balance sheet and…
02 Aug 23
Under the terms of the agreement, ProQR will get an initial payment of €12.5m and will also be…
31 Jul 23
Reata is a global biopharmaceutical company dedicated to advancing novel therapeutics for individuals facing serious or life-threatening diseases…
25 Jul 23
Upon conclusion of the deal, Quince will fund the EryDex through the Phase 3 clinical trial under special…
19 Jul 23
The products involved in the deal include FLAREX, NATACYN, TOBRADEX ST, VERKAZIA, ZERVIATE, and non-prescription brands FRESHKOTE and…
18 Jul 23
The disinterested members of the Pardes Board of Directors have unanimously determined that the acquisition by Purchaser is…
17 Jul 23
Combined company is expected to have cash balance of approximately $170m at close, which is expected to provide…
14 Jul 23
The acquisition of Continuum further reinforces Aspirion's market leadership in complex claims management specific to MVA and TPL…
12 Jul 23
The Acquisition was completed on July 11, 2023, US Eastern Time, as follows, and Iveric Bio has become…
07 Jul 23
CorEvitas offers regulatory-grade, real-world evidence solutions to biotechnology and pharmaceutical companies with objective data and clinical insights in…